201 related articles for article (PubMed ID: 12724846)
1. Inducing remission in inflammatory bowel disease.
Drug Ther Bull; 2003 Apr; 41(4):30-2. PubMed ID: 12724846
[TBL] [Abstract][Full Text] [Related]
2. Appropriateness of immunosuppressive drugs in inflammatory bowel diseases assessed by RAND method: Italian Group for IBD (IG-IBD) position statement.
Caprilli R; Angelucci E; Cocco A; Viscido A; Annese V; Ardizzone S; Biancone L; Castiglione F; Cottone M; Meucci G; Paoluzi P; Papi C; Sturniolo GC; Vecchi M
Dig Liver Dis; 2005 Jun; 37(6):407-17. PubMed ID: 15893279
[TBL] [Abstract][Full Text] [Related]
3. Maintenance drugs for inflammatory bowel disease.
Drug Ther Bull; 2001 Dec; 39(12):91-5. PubMed ID: 11799594
[TBL] [Abstract][Full Text] [Related]
4. Maintenance of remission in Crohn's disease: current and emerging therapeutic options.
Brookes MJ; Green JR
Drugs; 2004; 64(10):1069-89. PubMed ID: 15139787
[TBL] [Abstract][Full Text] [Related]
5. [Classical medications in the treatment of inflammatory bowel diseases].
Duvnjak M; Bilić A; Barsić N; Tomasić V; Stojsavljević S
Acta Med Croatica; 2013 Apr; 67(2):111-24. PubMed ID: 24471294
[TBL] [Abstract][Full Text] [Related]
6. [Current status of treatment of inflammatory bowel disease].
Rodríguez-Moranta F; Soriano-Izquierdo A; Guardiola J
Cir Esp; 2007 Nov; 82(5):254-9. PubMed ID: 18021623
[TBL] [Abstract][Full Text] [Related]
7. Advances in Pediatric Inflammatory Bowel Disease.
Maxwell EC; Grossman AB
Adolesc Med State Art Rev; 2016; 27(1):57-74. PubMed ID: 27363233
[No Abstract] [Full Text] [Related]
8. [Inflammatory bowel diseases (IBD) -- critical discussion of etiology, pathogenesis, diagnostics, and therapy].
Ochsenkühn T; Sackmann M; Göke B
Radiologe; 2003 Jan; 43(1):1-8. PubMed ID: 12552369
[TBL] [Abstract][Full Text] [Related]
9. The long-term outcome of anti-tumor necrosis factor-α therapy related to fecal calprotectin values during induction therapy in pediatric inflammatory bowel disease.
Kolho KL; Sipponen T
Scand J Gastroenterol; 2014 Apr; 49(4):434-41. PubMed ID: 24597837
[TBL] [Abstract][Full Text] [Related]
10. [Medical management of inflammatory bowel disease: consensus and controversies].
Bouhnik Y
Gastroenterol Clin Biol; 2003 Mar; 27(3 Suppl):S87-91. PubMed ID: 12704301
[No Abstract] [Full Text] [Related]
11. [New therapies for inflammatory bowel disease].
Matsui T
Nihon Shokakibyo Gakkai Zasshi; 2005 Jul; 102(7):855-65. PubMed ID: 16038431
[No Abstract] [Full Text] [Related]
12. Review article: Infliximab therapy for inflammatory bowel disease--seven years on.
Rutgeerts P; Van Assche G; Vermeire S
Aliment Pharmacol Ther; 2006 Feb; 23(4):451-63. PubMed ID: 16441465
[TBL] [Abstract][Full Text] [Related]
13. Combining infliximab with methotrexate for the induction and maintenance of remission in refractory Crohn's disease: a controlled pilot study.
Schröder O; Blumenstein I; Stein J
Eur J Gastroenterol Hepatol; 2006 Jan; 18(1):11-6. PubMed ID: 16357613
[TBL] [Abstract][Full Text] [Related]
14. Review article: treatment algorithms to maximize remission and minimize corticosteroid dependence in patients with inflammatory bowel disease.
Panaccione R; Rutgeerts P; Sandborn WJ; Feagan B; Schreiber S; Ghosh S
Aliment Pharmacol Ther; 2008 Sep; 28(6):674-88. PubMed ID: 18532990
[TBL] [Abstract][Full Text] [Related]
15. [Drug therapy of Crohn's disease: slowly increase or start aggressively right away?].
Bischoff A
MMW Fortschr Med; 2010 Jan; 152(1-2):20. PubMed ID: 20302159
[No Abstract] [Full Text] [Related]
16. [Therapy of chronic inflammatory bowel diseases].
Stange EF
Praxis (Bern 1994); 2002 Nov; 91(47):2029-39. PubMed ID: 12501498
[TBL] [Abstract][Full Text] [Related]
17. Inflammatory bowel disease: current therapeutic options.
Domènech E
Digestion; 2006; 73 Suppl 1():67-76. PubMed ID: 16498254
[TBL] [Abstract][Full Text] [Related]
18. [Chronic inflammatory bowel disease: Crohn's disease and ulcerative colitis].
Fiasse R; Denis MA; Dewit O
J Pharm Belg; 2010 Mar; (1):1-9. PubMed ID: 20432590
[TBL] [Abstract][Full Text] [Related]
19. General principles of medical therapy of inflammatory bowel disease.
Friedman S
Gastroenterol Clin North Am; 2004 Jun; 33(2):191-208, viii. PubMed ID: 15177534
[TBL] [Abstract][Full Text] [Related]
20. Serum concentrations after switching from originator infliximab to the biosimilar CT-P13 in patients with quiescent inflammatory bowel disease (SECURE): an open-label, multicentre, phase 4 non-inferiority trial.
Strik AS; van de Vrie W; Bloemsaat-Minekus JPJ; Nurmohamed M; Bossuyt PJJ; Bodelier A; Rispens T; van Megen YJB; D'Haens GR;
Lancet Gastroenterol Hepatol; 2018 Jun; 3(6):404-412. PubMed ID: 29606564
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
